Entity

Hemostatics Pharmaceuticals

Biotechnology - Therapeutics and Diagnostics

Associated Company

 

Hemostatics Pharmaceuticals S.L. is an emerging biotechnology company developing CM-352, a novel antifibrinolytic agent to reduce bleeding in lifethreatening and disabling haemorrhagic conditions.

 

With a new mechanism of action to inhibit fibrinolysis, its patented preclinical candidate is addressing significant unmet medical needs (e.g. IntraCranial Haemorrhage where other treatments are still suboptimal).

+34 608 087 655

info@hemostatics.com

hemostatics.com


Contact person: Nicolas Saglio